NEXGEL, Inc. (NXGLW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NEXGEL, Inc. (NXGLW) trades at $0.0229. NEXGEL, Inc. specializes in manufacturing and selling hydrogels for various applications, including wound care and cosmetics. Market cap: $1.78M, Sector: Unknown.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for NXGLW: NXGLW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NXGLW against Unknown peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on NXGLW.
How is this calculated? →NEXGEL, Inc. (NXGLW) Business Overview & Investment Profile
NEXGEL, Inc. manufactures and sells high water content hydrogels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. Operating through its Nexgel and CG labs segments, the company offers over-the-counter solutions and develops advanced medical products like NEXDrape and NEXDerm, positioning itself in the broader healthcare and beauty markets.
What Is the Investment Thesis for NXGLW?
NEXGEL, Inc. presents a focused investment opportunity within the specialized hydrogel market, targeting wound care, medical diagnostics, and cosmetic applications. With a gross margin of 40.8%, the company demonstrates potential for profitability, although its current profit margin is -24.7% and ROE is -52.8%. Key to NEXGEL's growth is the successful development and commercialization of products like NEXDrape and NEXDerm, which address specific needs in the medical sector. The company's debt-to-equity ratio of 57.24 indicates a moderate level of leverage. A primary risk lies in achieving profitability and managing cash flow, given the current negative free cash flow of $-0.00B. The company's beta of 0.62 suggests lower volatility compared to the market. Successful penetration into the wound care and cosmetic markets, coupled with efficient management of resources, will be crucial for realizing shareholder value.
Based on FMP financials and quantitative analysis
NXGLW Key Highlights
Gross Margin of 40.8% indicates potential for profitability in hydrogel products.
- Debt-to-Equity Ratio of 57.24 suggests a moderate level of financial leverage.
- Developing NEXDrape and NEXDerm targets specific needs in the medical sector.
- Profit Margin of -24.7% indicates current challenges in achieving profitability.
- Free Cash Flow of $-0.00B highlights the need for improved cash management.
What Are NXGLW's Key Strengths?
Specialized expertise in hydrogel technology.
- Proprietary electron beam cross-linking process.
- Diverse product applications across healthcare and cosmetics.
- Development of innovative medical products.
What Are NXGLW's Weaknesses?
Negative profit margin and ROE.
- Limited market presence compared to larger competitors.
- Dependence on successful commercialization of new products.
- Negative free cash flow.
What Could Drive NXGLW Stock Higher?
Regulatory approvals for NEXDrape and NEXDerm, potentially expanding market access.
- Expansion of distribution channels for Medagel and Lumagel Beauty products.
- Development and launch of new hydrogel-based products for wound care and cosmetics.
What Are the Key Risks for NXGLW?
Financial-distress signal — its Altman Z-Score of -1.78 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to achieve profitability and manage cash flow effectively.
- Competition from larger companies with greater resources and market share.
- Regulatory challenges in obtaining approvals for medical products.
- Dependence on successful commercialization of new products to drive revenue growth.
What Are the Growth Opportunities for NXGLW?
- Expansion in Wound Care Market: The global wound care market is projected to reach $22 billion by 2027. NEXGEL's Medagel brand and its development of NEXDrape and NEXDerm position it to capture a share of this growing market. Successful clinical trials and regulatory approvals for NEXDrape and NEXDerm could significantly boost revenue within the next 2-3 years.
- Penetration of the Cosmetics Industry: The global cosmetics market is expected to reach $463.5 billion by 2027. NEXGEL's Lumagel Beauty brand and its expertise in hydrogels provide an opportunity to develop innovative skincare and cosmetic products. Strategic partnerships with established cosmetic companies could accelerate market entry and brand recognition over the next 1-2 years.
- Strategic Partnerships and Collaborations: Collaborating with larger healthcare or cosmetic companies can provide NEXGEL with access to broader distribution networks and increased market reach. These partnerships can also facilitate joint product development and technology licensing, potentially leading to new revenue streams within the next 2-3 years.
- Geographic Expansion: Currently focused on the United States, NEXGEL has the opportunity to expand its sales and distribution to international markets. Europe and Asia-Pacific offer significant growth potential for its wound care and cosmetic products. Establishing a presence in these regions could drive revenue growth over the next 3-5 years.
- Development of Novel Hydrogel Applications: Investing in research and development to explore new applications for its hydrogel technology can create new market opportunities. This includes developing hydrogels for drug delivery, medical devices, and other specialized applications. Successful innovation in this area could lead to significant long-term growth and competitive advantages.
What Threats Does NXGLW Face?
- Competition from larger companies with greater resources.
- Regulatory hurdles for medical products.
- Fluctuations in raw material costs.
- Potential product liability claims.
What Are NXGLW's Competitive Advantages?
- Specialized expertise in high water content hydrogels.
- Proprietary electron beam cross-linking technology.
- Established brands in wound care and cosmetics.
- Development of innovative medical products like NEXDrape and NEXDerm.
What Does NXGLW Do?
NEXGEL, Inc., established in 2009 and based in Langhorne, Pennsylvania, specializes in the development, manufacturing, and sale of high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. These hydrogels are utilized across a diverse range of applications, including wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates through two primary segments: Nexgel and CG labs. Through these segments, NEXGEL offers a variety of over-the-counter remedy solutions, such as products for blister treatment and pain relief, as well as beauty and cosmetic solutions marketed under brands like Lumagel Beauty, Kenkoderm and Silly George. NEXGEL is also actively involved in the development of innovative medical products. These include NEXDrape, an incise surgical drape designed to protect patients with impaired skin during surgical procedures, and NEXDerm, an adhesive tape engineered to securely hold central lines, intravenous tubes, and other medical devices in place before, during, and after medical treatments. Furthermore, NEXGEL engages in converting and packaging services, providing comprehensive solutions for its clients. The company was formerly known as AquaMed Technologies, Inc., before rebranding to NEXGEL, Inc. in November 2019 to better reflect its focus on hydrogel technology. NEXGEL aims to leverage its expertise in hydrogels to address unmet needs in the healthcare and beauty industries.
What Products and Services Does NXGLW Offer?
- Manufactures high water content hydrogels.
- Utilizes electron beam cross-linking technology.
- Develops hydrogels for wound care applications.
- Creates hydrogels for medical diagnostics.
- Produces hydrogels for transdermal drug delivery.
- Offers hydrogels for cosmetic applications.
- Engages in converting and packaging services.
How Does NXGLW Make Money?
- Manufacturing and selling hydrogel-based products.
- Generating revenue through over-the-counter remedy solutions.
- Developing and commercializing advanced medical products.
- Providing converting and packaging services.
What Industry Does NXGLW Operate In?
NEXGEL, Inc. operates within the broader healthcare and cosmetics industries, focusing on hydrogel-based products. The market for advanced wound care and drug delivery systems is growing, driven by an aging population and increasing demand for innovative medical solutions. The cosmetics industry also presents opportunities for hydrogel-based products, particularly in skincare and beauty applications. Competition includes companies specializing in wound care, medical adhesives, and cosmetic ingredients. NEXGEL aims to differentiate itself through its high water content hydrogels and electron beam cross-linking technology.
Who Are NXGLW's Key Customers?
- Healthcare providers and hospitals.
- Cosmetic companies and retailers.
- Patients requiring wound care solutions.
- Consumers seeking beauty and cosmetic products.
Company Profile
NEXGEL, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Langhorne, US. The company is led by CEO Adam R. Levy. NXGLW has traded publicly since 2021.
Financial Health
NEXGEL, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.78 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project NEXGEL, Inc. revenue of about $24.1M for fiscal 2026, with EPS near $-0.12.
NXGLW Financials
Bull Case vs Bear Case
Bull Case
- Insider buying activity has increased, indicating confidence in the company's future prospects.
- Recent product developments have garnered positive attention, enhancing the company's market position.
- Community sentiment has shifted positively, with discussions highlighting innovative technology and potential applications.
- Market perception is improving as NEXGEL gains traction in sectors like healthcare and consumer products.
Bear Case
- Concerns about the company's financial stability persist, with ongoing discussions about cash flow management.
- Recent social media sentiment shows skepticism regarding the scalability of NEXGEL's products in competitive markets.
- Some investors remain cautious due to historical volatility, which has created a bearish outlook in certain trading circles.
- Broader market trends and economic uncertainties may negatively impact investor confidence in NEXGEL.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NXGLW Latest News
No recent news available for NXGLW.
NXGLW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NXGLW.
Price Targets
Wall Street price target analysis for NXGLW.
NXGLW MoonshotScore
What does this score mean?
The MoonshotScore rates NXGLW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry UnknownCommon Questions About NXGLW (Unknown)
What does NEXGEL, Inc. do?
NEXGEL, Inc. specializes in the development, manufacturing, and sale of high water content hydrogels. These hydrogels are used in a variety of applications, including wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates through its Nexgel and CG labs segments, offering over-the-counter remedies and developing advanced medical products like NEXDrape and NEXDerm.
What do analysts say about NXGLW stock?
As of 2026-03-16, there is no available analyst coverage for NXGLW. Given the lack of analyst ratings, investors should conduct their own thorough research and due diligence. Key valuation metrics to consider include revenue growth, gross margin, and cash flow. Investors should also monitor the company's progress in commercializing new products and expanding its market presence.
What are the main risks for NXGLW?
NEXGEL faces several key risks, including the challenge of achieving profitability and managing cash flow effectively, as indicated by its negative profit margin and free cash flow. The company also faces competition from larger, more established companies with greater resources and market share. Regulatory hurdles in obtaining approvals for medical products, such as NEXDrape and NEXDerm, pose another significant risk.
What are the key factors to evaluate for NXGLW?
Evaluate NXGLW on fundamentals, analyst consensus, and risk factors. NEXGEL, Inc. presents a focused investment opportunity within the specialized hydrogel market, targeting wound care, medical diagnostics, and cosmetic applications. Not financial advice.
How frequently does NXGLW data refresh on this page?
NXGLW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NXGLW's recent stock price performance?
NEXGEL, Inc. (NXGLW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in hydrogel technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NXGLW overvalued or undervalued right now?
NEXGEL, Inc. (NXGLW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NXGLW before investing?
Before investing in NEXGEL, Inc. (NXGLW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial data is as of the latest available reporting period.